Prestige Plans ‘Strong Price Competitiveness’ For Its Adalimumab Biosimilar
Discloses Phase I Details And Phase III Plans Ahead Of Filings In EU And US
Executive Summary
As Prestige BioPharma announced plans for Phase I and Phase III trials of its PBP1502 proposed adalimumab biosimilar, as well as expected filing dates in the EU and US, the company outlined how it believes its proprietary technology will allow its Humira rival to compete aggressively on price.
You may also be interested in...
‘Rapid Adoption’ Expected For US Humira Biosimilars
Uptake is expected to be “rapid” once Humira biosimilars launch in the US, according to Sean McGowan, senior director of biosimilars at AmerisourceBergen. Meanwhile, milestone first approvals for interchangeable and ophthalmic biosimilars show that the US biosimilars market is moving in the right direction, he tells Generics Bulletin in an exclusive Q&A.
Prestige Invests $152m To Build Landmark R&D Center In South Korea
Prestige BioPharma has announced a memorandum of understanding with the city of Busan, in South Korea, to build a 45,000 sq m R&D center, including to “accelerate the development of innovative antibody drugs.”
Prestige And Pharmapark Add Bevacizumab To Russia Collaboration
Russia’s Pharmapark has added Prestige BioPharma’s HD204 biosimilar bevacizumab product to the firms’ commercialization partnership, two years after kicking off the partnership with trastuzumab.